Recent News

• 11.05.2026 - iMDx to Release Third Quarter Results on November 16, 2026
• 10.14.2026 - iMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx Launch
• 10.12.2026 - iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings
• 09.02.2026 - iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference
• 08.11.2026 - Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing
• 08.10.2026 - IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
• 08.04.2026 - iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference
• 07.23.2026 - iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publication
• 07.16.2026 - Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio
• 06.29.2026 - IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper

Recent Filings

• 09.21.2026 - 8-K Current report
• 08.10.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.10.2026 - 8-K Current report
• 08.10.2026 - EX-99.1 EX-99.1
• 07.24.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 07.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.17.2026 - 8-K Current report
• 06.15.2026 - 4 Statement of changes in beneficial ownership of securities